EP3626233A1 — Prion-free nanoparticle compositions and methods
Assigned to Abraxis Bioscience LLC · Expires 2020-03-25 · 6y expired
What this patent protects
Provided herein is a composition comprising nanoparticles comprising a substantially water insoluble pharmacologically active agent coated with albumin, and a ligand capable of binding to a prion protein. Also provided is a mixture comprising an albumin solution, an organic phase…
USPTO Abstract
Provided herein is a composition comprising nanoparticles comprising a substantially water insoluble pharmacologically active agent coated with albumin, and a ligand capable of binding to a prion protein. Also provided is a mixture comprising an albumin solution, an organic phase comprising a substantially water insoluble pharmacologically active agent dispersed in an organic solvent, and a ligand capable of binding a prion protein.
Drugs covered by this patent
- Rapamune (sirolimus) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.